Futura Medical PLC (AIM:FUM, OTC:FAMDF) says interim CEO Alex Duggan is leading a careful review of the business. He says Eroxon sales started slower than expected but the product is now in 25 countries, with new products in development.
Tissue Regenix Group PLC (AIM:TRX) posted half-year revenue of $13.8 million, down 6% from last year. Margins and profits slipped, but the group gained a European patent, new approvals for OrthoPure XT and added 32 distributors.
Incanthera PLC (AQSE:INC) has reported its final results and launched its Skin+CELL skincare range in August. The range achieved first revenues quickly, and the company aims to sell 100,000 units by March 2026 after a £508,000 fundraise.
Tower Resources PLC (AIM:TRP) says it is fully committed to drilling the NJOM-3 well in Cameroon. The well is now expected in early 2026, following progress on farm-out agreements and government approvals.
Zephyr Energy PLC (AIM:ZPHR, OTCQB:ZPHRF) says testing at its Paradox project delivered peak rates in the top 6% of US wells. The company posted $6.3 million in revenue in the first half and expects higher volumes in the second half with new wells.
Emmerson PLC (AIM:EML) is pursuing arbitration against Morocco over the Khemisset potash project. It’s seeking compensation of up to $2.2 billion and has secured $11 million in funding to support the case.
Follow us and subscribe on YouTube, our social channels and on proactiveinvestors.co.uk.
